NCT04486781: An ongoing trial by Vasgene Therapeutics, Inc
This trial is ongoing. It must report results 1 year from now.
Full data
| Full entry on ClinicalTrials.gov | NCT04486781 |
|---|---|
| Title | A Phase II Trial of Pembrolizumab as Standard of Care + sEphB4-HSA in Chemotherapy Ineligible or Chemotherapy Refusing Patients With Metastatic Urothelial Carcinoma |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Aug. 14, 2020 |
| Completion date | Dec. 31, 2025 |
| Required reporting date | Dec. 31, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |